The distribution of the different chemerin forms in these ovarian carcinoma ascitic samples differ from those in plasma or serum, whether from participants with BMI < 25 or patients with BMI > 40 (Figure 1) in the fraction of active chemerins and the low proportion of intact precursor chem163S. This evidence concerns the gene RARRES2 and ovarian carcinoma.